Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Novartis Study Show Patients Having More Positive Response With Tasigna Compared to Gleevec
Dec. 15, 2011
Phase III clinical trial data presented today contribute to the growing evidence that adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are treated with Tasigna (nilotinib) have deeper levels of response compared to those treated with Gleevec (imatinib mesylate) tablets.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing